Back to results
US 12,589,132 B2Granted
CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
AssigneeFive Prime Therapeutics, Inc.
InventorsSusannah D. Barbee, Thomas Brennan, Barbara Sennino
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of treating PD-L1 negative tumors, the methods comprising administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1).
Claims22
A method of treating a PD-L1 negative tumor in a subject, the method comprising:
- (a) selecting a subject having a PD-L1 negative tumor, wherein the PD-L1 negative tumor comprises a tumor proportion score (TPS) of less than 5% as determined by immunohistochemistry (IHC), and
- (b) administering to the subject a composition comprising CD80 extracellular domain (ECD) fusion molecules, wherein the CD80 ECD fusion molecules comprise a human CD80 ECD and a human IgG1 Fc domain.
A method of treating a PD-L1 negative tumor in a human patient, the method comprising:
- (a) selecting a subject having a PD-L1 negative tumor, wherein the PD-L1 negative tumor comprises a tumor proportion score (TPS) of less than 5% as determined by immunohistochemistry (IHC), and
- (b) administering to the patient a composition comprising about 0.07 mg to about 70 mg CD80 extracellular domain (ECD) fusion molecules, wherein each of the CD80 ECD fusion molecules comprises the amino acid sequence of SEQ ID NO:5.
Dependencies are inferred from the claim text.